Phreesia
Biotechnology, Healthcare, Health Care
Phreesia is the trusted leader in patient activation, giving providers, health plans, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 120 million patient visits in 2022–more than 1 in 10 visits across the U.S.–scale that we believe allows us to make meaningful impact. Offering patient-driven d
Key facts
- Employees
- 2,100
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (PHR)
- Website
- phreesia.com
- Company page
Recent activity at Phreesia
- : Phreesia acquires AccessOne to enhance growth
- : SEC 8-K (8.01):
- : SEC 8-K (1.01): On April 30, 2026, AccessOne Funding, LLC, an indirect wholly-owned subsidiary of Phreesia, Inc., entered into Amendment No. 9 to the Receivables Purchase and Administration Agreement with PNC Bank and PNC Capital Markets. This Amendment modifies the terms under which PNC and its affiliates purchase receivables from AccessOne Funding, enabling the company to use proceeds for general corporate purposes. Significant terms include customary representations, covenants, and conditions that allow PNC to terminate the agreement upon specific defaults such as non-payment or material adverse effects. This agreement builds on Phreesia's strategic acquisition of AccessOne Holdings, enhancing its operational capabilities in receivables management.
- : SEC 8-K (1.01): On March 13, 2026, Phreesia, Inc. entered into a Credit Agreement with a total credit facility of up to $275 million, of which approximately $92.2 million was borrowed on the same date. The agreement allows for a senior secured revolving credit facility, with terms for interest based on either Term SOFR or a Base Rate, and includes specific sublimits for swingline loans and letters of credit. The proceeds are intended for purposes including the repayment of existing debts and general corporate needs. The agreement is guaranteed by certain subsidiaries and secured by a lien on the company's assets.
- : SEC 8-K (5.02): On February 23, 2026, Phreesia, Inc. announced the retirement of two members of its Board of Directors: Edward L. Cahill and Michael Weintraub. Both directors submitted notices on the same date stating they will retire at the end of their current terms and will not seek re-election at the upcoming 2026 Annual Meeting. Their retirements were not due to disagreements with the Board or management. Additionally, the company appointed Jon Kessler to the Board effective April 6, 2026. Kessler will receive restricted stock units valued at $40,041, vesting within a year, and an initial new hire grant of $185,000 with a four-year vesting schedule. This restructuring could influence board dynamics and strategic direction as the company prepares for its annual meeting.
- : SEC 8-K (2.01): On November 12, 2025, Phreesia, Inc. completed a merger transaction as per the Agreement and Plan of Merger dated August 29, 2025. In this transaction, its wholly-owned subsidiary, Ace Merger Sub, Inc., merged with AccessOne Parent Holdings, Inc., with AccessOne becoming the surviving corporation. This merger allows Phreesia to expand its operations and product offerings, significantly impacting its market presence. The strategic implications of this merger could enhance Phreesia's capabilities in healthcare technology by integrating AccessOne’s services into its operations.
- : SEC 8-K (1.01): On November 9, 2025, the Company entered into a Bridge Credit Agreement as part of the financing for the AccessOne Acquisition. This agreement involves a 364-day secured term loan of $110 million provided by Goldman Sachs Bank USA and other lenders. The proceeds will be used mainly to fund part of the AccessOne acquisition costs and related expenses. The loan bears interest based on the Secured Overnight Financing Rate plus an applicable margin, along with duration fees if the loan remains outstanding for extended periods. The loan is guaranteed by the Company's subsidiaries and secured by liens on the Company’s assets, with specific conditions governing prepayments and additional debt arrangements. This financing strategy indicates a significant move by the Company to bolster its acquisition capabilities.
- : Phreesia Launches Integration with Oracle Health EHR to Enhance Patient Experience and Operations Efficiency.
- : Phreesia Renews Contract with CMS for Patient Activation Measure (PAM)
- : Phreesia Names Jack Callahan as Chief Technology Officer, Succeeding Dan Nathan
Phreesia funding history
| Date | Round | Amount |
|---|---|---|
| Dec 2017 | Venture | $34.0M |
| Nov 2017 | Venture | $17.0M |
Leadership
- Scott Perricelli, Director
- Dusty Lieb, Director
- Alan Spoon, Director
- Victor Kats, Director
- Michael Weintraub, Director
- Edward Cahill, Director
- Chaim Indig, Executive Officer, Director
- Scott Perricelli, Director
- William Conroy, Director
- Alan Spoon, Director
- Victor Kats, Director
- Michael Weintraub, Director
Verified email and direct lines for Phreesia’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Phreesia files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Phreesia in the news
- Phreesia Named to TIME’s 2026 List of the World’s Top HealthTech Companies - Business Wire (Sep 30, 2026)
- Phreesia Network Solutions Launches ProviderConnect, a Pioneering Offering to Engage Clinicians When It Matters Most - Business Wire (Mar 03, 2026)
- I declined to share my medical data with advertisers at my doctor’s office. One company claimed otherwise - STAT (Apr 07, 2023)
- Patients Getting Weight Loss Information from Advertising as Opposed to Doctors: New Study Suggests - Pharmaceutical Executive (Jun 25, 2024)
- Phreesia Announces Fourth Quarter Fiscal 2026 Results - Business Wire (Mar 30, 2026)
- Phreesia has strong public debut as 2nd digital health IPO in 2019 - Fierce Healthcare (Jul 19, 2019)
- Phreesia’s Tara Sheehy Named to MM+M Women to Watch - Business Wire (Mar 05, 2026)
- Phreesia’s ProviderConnect Audiences are Now Available in the DeepIntent Audience Marketplace - Business Wire (Sep 14, 2026)
Companies similar to Phreesia
- Optimize Systems · Biotechnology, Healthcare, Health Care, Information Technology, Medical
- pulseData, Inc. · Biotechnology, Healthcare, Health Care, Information Technology, Medical
- Dror Ortho-Design · Biotechnology, Healthcare, Health Care, Information Technology, Medical
- Artivion · Biotechnology, Healthcare, Health Care, Medical
- ShockWave Medical · Biotechnology, Healthcare, Health Care, Medical
About Phreesia: questions and answers
What does Phreesia do?
Phreesia is the trusted leader in patient activation, giving providers, health plans, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 120 million patient visits in 2022–more than 1 in 10 visits across the U.S.–scale that we believe allows us to make meaningful impact. Offering patient-driven d
How many employees does Phreesia have?
Phreesia has about 2,100 employees.
Has Phreesia raised funding?
Yes. Fundz has recorded 2 funding events for Phreesia. The most recent, $34.0M, was in Dec 2017.
What is the latest news on Phreesia?
On Jun 07, 2026, Phreesia acquires AccessOne to enhance growth
Is Phreesia a public company?
Yes. Phreesia is publicly traded under the ticker PHR.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy